Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $23.43 Consensus Target Price from Analysts

Cellebrite DI Ltd. (NASDAQ:CLBT) has been given an average recommendation of “Buy” by the eight research firms that are currently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.43.

A number of brokerages recently weighed in on CLBT. Craig Hallum upped their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Friday, February 14th. Finally, Lake Street Capital upped their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th.

Institutional Investors Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in Cellebrite DI in the third quarter valued at about $27,000. Advisors Asset Management Inc. raised its stake in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after buying an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC raised its stake in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after buying an additional 4,118 shares during the last quarter. Gen Wealth Partners Inc purchased a new stake in Cellebrite DI in the fourth quarter valued at about $85,000. Finally, NewEdge Advisors LLC raised its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after buying an additional 3,352 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Trading Up 0.3 %

Shares of CLBT stock opened at $18.56 on Wednesday. Cellebrite DI has a twelve month low of $10.24 and a twelve month high of $26.30. The stock has a market capitalization of $3.82 billion, a price-to-earnings ratio of -13.35, a P/E/G ratio of 4.27 and a beta of 1.47. The stock has a fifty day simple moving average of $22.31 and a two-hundred day simple moving average of $19.57.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Research analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.